CS
PVLA

Candriam SCA’s Palvella Therapeutics PVLA Stock Holding History

Candriam SCA’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,398
Closed -$316K – 880
2023
Q1 		$316K Sell
4,398
-7,375
-63% -$854K ﹤0.01% 850
2022
Q4 		$979K Sell
11,773
-1,500
-11% -$121K 0.01% 699
2022
Q3 		$1.22M Hold
13,273
– – 0.01% 674
2022
Q2 		$1.99M Hold
13,273
– – 0.02% 509
2022
Q1 		$3.22M Hold
13,273
– – 0.02% 439
2021
Q4 		$4.01M Hold
13,273
– – 0.03% 401
2021
Q3 		$5.49M Hold
13,273
– – 0.04% 385
2021
Q2 		$4.07M Sell
13,273
-15,136
-53% -$3.32M 0.03% 447
2021
Q1 		$5.46M Hold
28,409
– – 0.05% 355
2020
Q4 		$5.68M Sell
28,409
-439
-2% -$91.3K 0.05% 364
2020
Q3 		$4.78M Sell
28,848
-470
-2% -$107K 0.04% 359
2020
Q2 		$7.27M Buy
29,318
+10,716
+58% +$2.51M 0.08% 268
2020
Q1 		$5.27M Buy
18,602
+1
+0% +$252 0.06% 333
2019
Q4 		$5.39M Buy
18,601
+10,351
+125% +$2.87M 0.06% 339
2019
Q3 		$2.25M Buy
+8,250
New +$3.19M 0.03% 462

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Candriam SCA's PVLA Position: Q2 2023 in Review

Candriam SCA sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 4,398 shares — an estimated $316K sold.

Candriam SCA first reported a position in PVLA in Q3 2019 and held it in 15 quarters. The position peaked at $7.27M in Q2 2020. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • Candriam SCA reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 4,398 Palvella Therapeutics shares in Q2 2023, an estimated $316K.
  • Candriam SCA first reported a position in Palvella Therapeutics in Q3 2019 and held it in 15 quarters.
  • Candriam SCA's Palvella Therapeutics position peaked at $7.27M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.